Research Advocate Seana Roubinek attended the 2015 American Association of Cancer Research Annual Meeting in April. Here is her report: “As a two-time cancer ovarian cancer survivor, I have had the great opportunity to get involved in legislative advocacy as well as the Survivors Teaching Students® program through the Ovarian Cancer National Alliance. Being selected … Continued
FOR IMMEDIATE RELEASE May 12, 2015 Contact: Lisa Mauti lmauti@ovariancancer.org (202) 517-6410 New Affordable Care Act guidance says women with ovarian cancer can receive free genetic counseling, testing WASHINGTON, DC—Yesterday, the U.S. Department of Health and Human Services, Labor and Treasury issued new guidance to clarify services and coverage available under the Affordable Care Act. … Continued
New Affordable Care Act guidance says women with ovarian cancer can receive free genetic counseling, testing. On May 11, 2015, the U.S. Department of Health and Human Services, Labor and Treasury issued new guidance to clarify services and coverage available under the Affordable Care Act. Before today, only women with a family history of ovarian and breast cancer were eligible for genetic testing and counseling free from additional out-of-pocket expense. Click the plus sign to read on...
OCRF’s Super Saturday NY, now heading into its 18th year, has long been the summertime event in the Hamptons. And on May 16th, guests on the West Coast will enjoy an unforgettable day of deep discounts, luxury experiences, and activities for the whole family, as OCRF’s Super Saturday LA returns for the second year to … Continued
(May 5, 2015) Data from a large clinical trial shows that a personalized method for interpreting blood tests identifies more ovarian cancer cases than a generalized approach. The results from the study will be published in the Journal of Clinical Oncology. Using an algorithm to analyze changes in the level of CA-125 (a protein in … Continued
(April 29, 2015) A study published in JAMA Oncology last Saturday concluded that an oophorectomy, the surgery to remove ones ovaries, has a substantial impact on survival rates for those diagnosed with stage I or II breast cancer who also tested positive for the BRCA1 mutation. Involved in the study were 676 women, 345 of whom had … Continued
After Susan Poorman Blackie’s diagnosis of ovarian cancer on Valentine’s Day in 2012 left her completely blindsided, she realized that she had to do something to improve the awareness and treatment options for ovarian cancer. Susan’s remarkable journey and commitment to making a difference in the lives of those with ovarian cancer led to the … Continued
On April 23, the drug manufacturer Mylan N.V. announced a voluntary nationwide recall of select lots of several drugs used in the treatment of ovarian cancer. The nationwide recall includes several formulations of injectable gemcitabine and cytarabine. While no adverse events have been reported with the use of these drugs, patients who may be experiencing problems related to these drugs should contact their physicians. Expand the post for more information about the recall.
Ovarian Cancer Research Fund, Ovarian Cancer National Alliance and National Ovarian Cancer Coalition Team-Up to Fund Game-Changing Ovarian Cancer Research Today the members of the new Stand Up To Cancer-Ovarian Cancer Research Fund-Ovarian Cancer National Alliance-National Ovarian Cancer Coalition Translational Research Dream Team were announced. The Dream Team will focus on “DNA Repair Therapies for … Continued
April 20, 2015: The Ovarian Cancer Dream Team has been chosen! The Dream Team will focus on “DNA Repair Therapies for Ovarian Cancer,” building on recent advances that have identified DNA repair as a common weakness in ovarian cancer. Researchers will also explore the prevention and early detection of ovarian cancer by developing a … Continued
(April 16, 2015) The Society of Gynecologic Oncology has published recommendations for prevention of ovarian cancer in Cancer. Strategies include oral contraceptive use and tubal sterilization, as well as genetic counseling and testing for women from high-risk families. Read the abstract in ACS Journals.
(April 15, 2015) Doctors have long recognized that women with mutations in two particular genes – BRCA1 and BRCA2 – have a higher risk of breast and ovarian cancer. Now they are starting to figure out which mutations are worse than others. They have even discovered that some of these mutations may reduce a woman’s … Continued
Get email updates about research news, action alerts, and ways to join the fight.
